How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots

The post How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs appeared first on Investor’s Business Daily.